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Background: The combination of a radioisotope with a chemotherapeutic agent in a   liposomal 
carrier (ie, Indium-111-labeled polyethylene glycol pegylated liposomal vinorelbine, [111In-VNB-
liposome]) has been reported to show better therapeutic efficiency in tumor growth suppression. 
Nevertheless, the challenge remains as to whether this therapeutic effect is attributable to 
the combination of a radioisotope with chemotherapeutics. The goal of this study was to 
investigate the pharmacokinetics, biodistribution, and correlation of Indium-111 radioactivity 
and vinorelbine concentration in the 111In-VNB-liposome.
Methods: The VNB-liposome and 111In-VNB-liposome were administered to rats. Blood, liver, 
and spleen tissue were collected to determine the distribution profile of the 111In-VNB-liposome. 
A liquid chromatography tandem mass spectrometry system and gamma counter were used to 
analyze the concentration of vinorelbine and radioactivity of Indium-111.
Results: High uptake of the  111In-VNB-liposome in the liver and spleen demonstrated the 
properties of a nanosized drug delivery system. Linear regression showed a good correlation 
(r = 0.97) between Indium-111 radioactivity and vinorelbine concentration in the plasma of 
rats administered the 111In-VNB-liposome.
Conclusion: A significant positive correlation between the pharmacokinetics and biodistribu-
tion of 111Indium radioactivity and vinorelbine in blood, spleen, and liver was found follow-
ing administration of the  111In-VNB-liposome. The liposome efficiently encapsulated both 
vinorelbine and Indium-111, and showed a similar concentration-radioactivity time profile, 
indicating the correlation between chemotherapy and radiotherapy could be identical in the 
liposomal formulation.
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Introduction
Vinorelbine is a semisynthesized vinca alkaloid belonging to the Catharanthus 
alkaloid group.1 Vinca alkaloids are potent anticancer agents that act by binding to 
tubulin and preventing tubulin assembly into microtubules, that can ultimately lead 
to mitotic inhibition and induction of apoptosis.2 Vinorelbine has been approved as 
a treatment for various cancers, including metastatic breast cancer and nonsmall cell 
lung cancer.3,4 Vinorelbine is better tolerated than other vinca alkaloids because of a 
lower propensity for axonal microtubules to cause neurotoxicity.5 Many studies have 
put effort into maintaining the vinorelbine concentration surrounding tumor cells in 
order to improve the anticancer activity of vinorelbine.6,7 Liposomal encapsulation is 
practical for vinorelbine to extend its circulation time and to increase its accumula-
tion in tumor tissue.
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The liposome is a drug carrier system that may prolong 
drug retention in the blood circulation. Liposomes consist 
of phospholipid bilayers and have an aqueous cavity in the 
inner phase, which can be a stable shelter for pharmacologic 
agents, including chemotherapeutic drugs used in cancer 
therapy, antisense oligonucleotides used in gene therapy, 
peptides used in the treatment of infectious diseases, antigens 
that stimulate an immune response, and radiopharmaceuticals 
used for targeting diagnosis and therapy.8–11 The application 
of a liposomal drug delivery system in cancer therapy has 
many advantages, such as increasing drug stability in vivo, 
enhancing drug bioavailability, and targeting the site of 
action.12,13
Radiolabeling technology has been utilized for drug 
development to evaluate the biodistribution and phar-
macokinetics of investigational new drugs. In addition, 
radioisotopes can be used for diagnostic and therapeutic 
purposes.10,14,15 Nowadays, finding the optimal strategy for 
cancer therapy is still a challenge.16 Concurrent or sequential 
combination of chemotherapy and external beam radio-
therapy is recognized as a standard therapeutic procedure 
for treating many cancers.17,18 The rationale for combining 
various therapeutic modalities is to expand the therapeutic 
index by synergistic drug effects and reducing the overlap-
ping spectrum of side effects or toxicity.19 Radionuclide 
therapy integrated into anticancer drug-loaded nanocar-
rier delivery systems may provide a potential therapeutic 
strategy for cancers.20
Previous reports on the encapsulation of Indium-111 into 
the vinorelbine liposome (111In-VNB-liposome) and 
    Rhenium-188 (188Re-DXR liposome) have shown that 
combination therapy can be realized and provides better 
tumor-targeting therapeutic activity.21–28 There are still no 
reports correlating the pharmacokinetics of a radiolabeled 
tracer and vinorelbine concentration. In this investigation, 
both the pharmacokinetics and biodistribution of the 
vinorelbine liposome (VNB-liposome) and 111In-VNB-
liposome are discussed. Results from two experiments show 
a correlation between vinorelbine concentration and Indium-
111 radioactivity.
Materials and methods
Materials
Methanol, ammonium formate, and formic acid were 
  purchased from Merck (Darmstadt, Germany). Vincamine, 
  heparin sodium, and 8-hydroxyquinoline (oxine) were obtained 
from Sigma-Aldrich (St Louis, MO). Aerrane (isoflurane) 
was   purchased from Baxter (San Juan, Puerto Rico), and 
  vinorelbine was obtained from Orient Europharma (Taipei, 
Taiwan). The VNB-liposome (NanoVNB) was kindly pro-
vided by the Taiwan Liposome Company (Taipei, Taiwan). 
Deionized water (Millipore, Bedford, MA) was used through-
out the entire experiment.
Preparation of VNB-liposome
Preparation of liposomes and the VNB-liposome has been 
previously described.21,29 Briefly, PEGylated liposomes 
were prepared from distearoyl phosphatidylcholine, 
  cholesterol, and PEG-DSPE (molar ratio 3:2:0.045). Small 
unilamellar vesicles (100 nm in diameter) were produced by 
a combination of the standard thin-film hydration method, 
the freeze-thaw method, and repeated extrusion. The extra-
liposomal salt was removed by a Sephadex™ G-50 column 
(Bio-Rad, Hercules, CA) and elution with histidine-sucrose 
buffer (pH 6.0). Vinorelbine, an anticancer agent was encap-
sulated into nanoliposomes using a polyanionic gradient. 
After removing the extraliposomal salt using a Sephadex 
G-50 column, vinorelbine was added immediately to the solu-
tion at a concentration of 3.5 mg/10 µmol of phospholipid. 
The mixture of liposomes and vinorelbine was incubated in a 
water bath at 60°C for 30 minutes with agitation at 100 rpm. 
After loading, the liposomal vinorelbine was sterilized by 
0.2 µm filtration and stored at 4°C–6°C before use. The mean 
particle size of the VNB-liposome and the concentration of 
vinorelbine in the VNB-liposome was 95.2 ± 4.9 nm and 
2.08 mg/mL, respectively.
Preparation of 111In-VNB-liposome
The method used to label VNB-encapsulated PEGylated 
liposomes with 111In-oxine has been detailed in a previous 
report.25 Briefly, 111In-oxine residue was dissolved in 20 µL 
of ethanol, added to 80 µL of distilled water, and then incu-
bated with 2 mL PEGylated VNB-liposomes for 30 minutes 
at 37°C. About 100 µL of reaction solution were loaded 
onto a column (40 × 8 mm, Bio-Rad) containing Sephadex 
G-50 fine gel and eluted with normal saline. The labeling 
efficiency was determined by dividing the radioactivity of 
the PEGylated VNB-liposome fractions after separation by 
total radioactivity before separation. The particle size of 111In-
VNB-liposome (after the radioactivity decay to background) 
was determined using an ultraviolet-visible spectrophoto-
meter (V-530; Jasco, Tokyo, Japan). The radiochemical purity 
values for the  111In-VNB-liposome were all greater than 
90%. The average particle size of the 111In-VNB-liposome 
was 102 ± 6.9 nm, which is similar to that of VNB-liposome 
(95.2 ± 4.9 nm).
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Experimental animals
Male Sprague-Dawley rats (National Yang-Ming University 
Animal Center, Taipei, Taiwan), were housed on a 12-hour 
light and 12-hour dark cycle. Free access to food (Laboratory 
Rodent Diet 5001, PMI Feeds, Richmond, IN) and water was 
allowed at all times. All animal protocols were approved by 
the Institutional Animal Care and Use Committee at National 
Yang-Ming University (Taipei, Taiwan) and the Institute 
of Nuclear Energy Research (Taoyuan, Taiwan). The rats 
weighed 250 ± 10 g. The animals were separated into two 
groups, one for pharmacokinetic experiments and the other 
for biodistribution experiments.
For the pharmacokinetics, ten rats (five rats per group) 
were anesthetized with 1.5% isoflurane, and each rat was 
given the VNB-liposome (containing vinorelbine 0.3 mg/kg) 
or 111In-VNB-liposome (vinorelbine 0.3 mg/kg, Indium-111 
2.22 MBq per rat) through the tail vein. A 0.3 mL blood 
sample was collected as blank plasma prior to drug admin-
istration, and further blood samples were collected at 0.25, 1, 
4, 24, 48, and 72 hours after drug administration. Following 
blood collection, radioactivity was measured using a Cobra 
II auto-gamma counter (1470 Wizard Gamma Counter; 
  Wallac, Turku, Finland). The percentage of injected dose per 
mL (% ID/g) was calculated by comparison with standards 
representing the injected dose per animal. Plasma samples 
were stored at −20°C before analysis.
For the biodistribution study, 30 rats (three rats at each 
time point in each group) were anesthetized with 1.5% 
  isoflurane, and each rat was given the VNB-liposome 
(containing vinorelbine 0.3 mg/kg) or 111In-VNB-liposome 
(vinorelbine 0.3 mg/kg, Indium-111 2.22 MBq per rat) 
through the tail vein. At 1, 4, 24, 48, and 72 hours following 
injection, the rats were sacrificed by CO2 asphyxiation and 
the liver and the spleen were collected, rinsed with normal 
saline, weighed, and the radioactivity was measured using 
the Cobra II auto-gamma counter. The %ID and the %ID/g 
were calculated by comparison with standards representing 
the injected dose per animal. The data were expressed as 
the mean ± standard deviation. The organs were preserved 
at −20°C for further treatment and vinorelbine analysis.
Sample preparation
Protein precipitation was used to extract vinorelbine from 
the rat plasma samples. Briefly, 240 µL of methanol with 
10 ng/mL of vincamine (as the internal standard) was added 
to 80 µL of collected plasma, and the mixture was vortexed 
for 10 minutes then centrifuged at 16,000 g and 4°C for 
10 minutes. The supernatant was collected and dried using 
a centrifugal vaporizer. The dried sample was reconstituted 
with 80 µL of 80% methanol, and filtered using a 0.2 µm 
filter (Millipore, Millex®-GV, Bedford, MA). The filtrate 
was analyzed using a liquid chromatography tandem mass 
spectrometry system. The standard samples were prepared 
in the same protein precipitation method by spiking stock 
solution (20 µL vinorelbine standard) in plasma (80 µL). The 
mixed sample was then added to 300 µL of methanol with 
10 ng/mL vincamine and followed the previous procedure, 
but was reconstituted with 100 µL of 80% methanol. The 
final filtrate was also analyzed using a liquid chromatography 
tandem mass spectrometry system.
Liver and spleen samples were extracted using a solid-
phase extraction cartridge (Oasis HLB, 1 mL, 10 mg). 
The organ samples were first homogenized (Polytron 
PT-MR 2100, Kinematica AG, Lucerne, Switzerland) with 
50% methanol (5:1 v/w for spleen and 3:1 v/w for liver) 
at 20,000 rpm for 10 minutes. The supernatant was obtained 
by centrifugation at 10,000 rpm for 10 minutes. A 100 µL 
supernatant sample was mixed with 100 µL of vincamine 
(5 ng/mL) and 800 µL of 1% formic acid. The mixture 
was loaded into a solid-phase extraction cartridge, washed 
with 10 mM ammonium formate, 20% methanol in 10 mM 
ammonium formate, and eluted with 90% methanol in 10 mM 
ammonium formate. The collected elution was dried using 
a centrifugal vaporizer, reconstituted with 100 µL of 80% 
methanol, and filtered using a 0.2 µm filter (Millipore). The 
filtrate was analyzed using a liquid chromatography tandem 
mass spectrometry system. The standard samples were 
prepared by the solid-phase extraction method using a spik-
ing stock solution (20 µL vinorelbine standard) in plasma 
(80 µL). The sample was mixed using the same solid-phase 
extraction preparation method. The final reconstituted sample 
was also analyzed using the liquid chromatography tandem 
mass spectrometry system.
Liquid chromatography-tandem  
mass spectrometry
The system consisted of a Waters 2690 Alliance LC with 
an automatic liquid chromatographic sampler and injector 
and a Micromass Quattro Ultima tandem quadrupole mass 
spectrometer (Micromass, Manchester, UK) equipped 
with an electrospray ionization interface which was in 
acquired positive mode. Ultrapure argon was used as the 
collision gas, and high-pure nitrogen was used as cone gas. 
Multiple-reaction monitoring analysis was used for quantita-
tion and the samples were quantified using peak area. The 
multiple-reaction monitoring transitions were m/z 779.2 to 
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m/z 122.0 for vinorelbine and m/z 355.2 to m/z 337.2 for 
vincamine, which was used as the internal standard. The 
electrospray ionization-tandem mass spectrometry para-
meters were set as follows: capillary voltage, 3.0 kV; source 
temperature, 110°C; desolvation temperature, 350°C; cone 
gas flow, 100 L/hour; and desolvation gas flow, 500 L/hour. 
To obtain optimal responses, the cone voltage was set at 
30 V, and the collision energy was adjusted to 20 eV for 
vinorelbine and 45 eV for the internal standard, vincamine. 
MassLynx 3.5 (Micromass) software was used for data 
processing. A Phenomenex Luna C18 column (5 µm and 
50 × 4.6 mm) maintained at an ambient temperature was 
used to separate the vinorelbine. The mobile phase consisted 
of 70% methanol and 30% 10 mM ammonia acetate with 
0.8% formic acid, and the flow rate was 0.2 mL/minute. The 
injection sample volume was 5 µL.
Method validation
Calibration curves were established using blank samples 
(plasma, liver, and spleen) spiked with different amounts 
of vinorelbine. Stock solution diluted with 50% methanol 
was used to form a series of concentrations from 25 to 
2500 ng/mL. The concentration-response relationship for 
this method indicated linearity over a concentration range of 
5–500 ng/mL, with a coefficient of determination (r2) of at 
least 0.999. The intra-assay and interassay variabilities were 
determined by quantitating six replicates at concentrations 
of 5, 10, 20, 50, 100, 200, and 500 ng/mL on the same day 
and consecutive days, respectively. The limit of detection 
was defined as a signal-to-noise ratio of 3, the lower limit of 
quantitation was defined as 10, and the lowest concentration 
of the linear regression defined the limit of quantitation. The 
accuracy (bias%) was calculated from the mean value of 
observed concentration (Cobs) and the nominal concentration 
(Cnom) as follows: accuracy (%) = [(Cobs − Cnom)/Cnom] × 100. 
The relative standard deviation (RSD) was calculated 
from the observed concentrations as follows: precision 
(%) = [standard deviation (SD)/Cobs] × 100. Accuracy and 
precision values within ±20% covering the actual range of 
experimental concentrations were considered acceptable.
Three sets of samples were prepared to evaluate the 
matrix effect and the recovery of the quantitative bioanalyti-
cal method:30
•	 Neat sample – samples were prepared using a vinorelbine 
standard solution diluted with normal saline to the target 
concentrations of 5, 50, and 500 ng/mL.
•	 Postextraction fortification – samples were prepared by 
spiking appropriate concentrations of standard solutions 
of vinorelbine to the postextracted blank plasma sample, 
with target concentrations of 5, 50, and 500 ng/mL.
•	 Pre-extraction fortification – samples were prepared by 
spiking appropriate concentrations of standard solutions 
of vinorelbine to the pre-extracted blank plasma sample 
with target concentrations of 5, 50, and 500 ng/mL. These 
samples were further processed by the protein precipita-
tion methods before analysis. By comparing the peak 
areas of set 1 and set 2, the data allow determination of 
the matrix effect, which represents ion suppression or 
enhancement association. By comparing the peak areas 
of set 2 and set 3, the data enable determination of the 
recovery sample treatment procedure.
Pharmacokinetic parameters  
and statistical analysis
The pharmacokinetic parameters were calculated by 
  WinNonlin (v 5.0.1; Pharsight Corporation, Mountain View, 
CA) and included half-life (t1/2), maximum concentration 
(Cmax), and area under the concentration-time curve (AUC). 
All data are presented as the mean ± standard deviation or the 
mean ± standard error of the mean. The unpaired t-test was 
used for group comparisons. Values of P ,0.05 were con-
sidered significant. Coefficient of correlation (r) was used to 
estimate the correlation between radioactivity of Indium-111 
and vinorelbine concentrations in this study.
Results
Method validation
Selectivity was confirmed by a chromatogram of a blank 
sample and a blank sample spiked with vinorelbine. Under 
the given conditions, vinorelbine was eluted at a retention 
time of 2.7 minutes for the plasma sample and 2.2 minutes 
for liver and spleen samples, and there was no interference 
at the same retention time. Liquid chromatography tandem 
mass spectrometry images of vinorelbine in plasma, liver, 
and spleen are shown in Figure 1. Calibration curves for 
vinorelbine were shown to have linear regression in the 
concentration range of 5 to 500 ng/mL for plasma, liver, 
and spleen, and a coefficient of determination (r2) .0.999 
for all curves, demonstrating good linear regression in the 
concentration range tested. Table 1 demonstrates that intra-
day and interday precisions (RSD%) were less than 13.5%, 
and accuracies (RE%) for intraday and interday assays were 
less than 16.0%. The signal-to-noise ratio of 3, defined as the 
limit of detection, was 0.25 ng/mL; that of 10, defined as the 
lower limit of quantification, was 0.83 ng/mL; and the lowest 
concentration of the linear regression, defined as the limit of 
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Figure 1 Typical liquid chromatography tandem mass spectrometry images of vinorelbine. (A) Blank plasma sample, (B) blank plasma spiked vinorelbine sample (200 ng/mL), 
(C) real plasma sample (156 ng/mL, t = 24 hours), (D) blank liver sample, (E) blank liver spiked vinorelbine sample (200 ng/mL), (F) real liver sample (141 ng/mL, t = 4 hours), 
(G) blank spleen sample, (H) blank spleen spiked vinorelbine sample (500 ng/mL), (I) real spleen sample (424 ng/mL, t = 1 hour). 
Note: The maximal signal intensities for plasma, liver and spleen samples were 9.0 × e5, 1.3 × e6, and 8.5 × e5, respectively.
quantification, was 5 ng/mL. The matrix effect and recovery 
for determination of vinorelbine are summarized in Table 2, 
and these results show that the detection and extraction meth-
ods for these samples were reliable and acceptable.
Pharmacokinetics of VNB-liposome
The vinorelbine concentration-time profile in the rat is shown 
in Figure 2. It is clear that in rats administered 0.3 mg/kg 
of the VNB-liposome, the concentration of vinorelbine 
gradually decreased over 24 hours, and the concentration of 
  vinorelbine at the 24-hour sampling point was 204 ± 64 ng/mL. 
  According to the time-concentration profile, the pharmacoki-
netic parameters were estimated as: t1/2 = 4.8 ± 1.2 hours; 
C0 = 6.27 ± 2.68 µg/mL; AUC0–24 h = 65.5 ± 26.6 h*µg/mL. 
These data are listed in Table 3.
The concentration of vinorelbine in the liver and spleen 
versus time was also observed in this investigation, and 
the results are shown in Figure 3. The concentration of 
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vinorelbine in these two organs could be maintained for 
at least 24 hours. The results also show that the concentra-
tion of vinorelbine in the spleen was significantly higher 
than that in the liver (P , 0.05). From the concentration-
time profile of these two organs, two parameters could be 
obtained: Cmax = 0.35 µg/g, AUC0–24 h = 5.26 h*µg/g and 
Cmax = 2.47 µg/g, AUC0–24 h = 47.0 h*µg/g for the liver and 
spleen, respectively.
Pharmacokinetics of 111In-VNB-liposome
The vinorelbine concentration-time profile of the rats admin-
istered 111In-VNB-liposome (0.3 mg/kg vinorelbine, Indium-
111 2.22 MBq/rat) was similar to that in rats administered 
0.3 mg/kg VNB-liposome (Figure 2). After administration 
of the 111In-VNB-liposome, the concentration of vinorelbine 
still reached 116 ± 77 ng/mL at 24 hours. From the time-
concentration profile, the pharmacokinetic parameters were 
obtained: t1/2 = 3.3 ± 1.3 hours; C0 = 7.15 ± 1.60 µg/mL; 
AUC0–24 h = 44.5 ± 31.0 h*µg/mL. These data are listed in 
Table 3. The radioactivity-time profile of the rats is demon-
strated in Figure 2. Radioactivity could be detected in rat plasma 
24 hours after administration of the  111In-VNB-  liposome, 
which was 0.7610 ± 0.3003 %ID/mL, and based on the profile, 
the pharmacokinetic parameters obtained were C0 = 8.88 ± 0.43 
%ID/mL and AUC0–24 h = 115.46 ± 16.83 h*%ID/mL.
The concentration of vinorelbine in the liver and 
spleen versus time are shown in Figure 3. The results 
were similar to that of rats administered the VNB-lipo-
some. From the concentration-time profile of these two 
organs, the pharmacokinetic parameters could be calcu-
lated as Cmax = 0.19 µg/g, AUC0–24 h = 3.54 h*µg/g and 
Cmax = 2.86 µg/g, AUC0–24 h = 57.5 h*µg/g for liver and spleen, 
respectively. The   radioactivity could also be detected, and 
based on the profile, the pharmacokinetic parameters were 
calculated as: Cmax = 4.8%ID/g, AUC0–24 h = 87.7 h*%ID/g and 
Cmax = 21.5%ID/g, AUC0–24 h = 418 h*%ID/g, respectively.
Radiolabeled tracer and vinorelbine 
concentration in 111In-VNB-liposome
The radioactivity-time profile clearly matched the   vinorelbine 
concentration-time profiles in 111In-VNB-liposome   experiments 
(Figure 2). This result showed that liposome encapsulated 
concurrently with Indium-111 and   vinorelbine did not affect 
Table 1 Intraday and interday assay for accuracy and precision for determination of vinorelbine
Intraday Interday
Cnom (ng/mL) Cobs (ng/mL) RSD (%)a Bias (%)b Cnom (ng/mL) Cobs (ng/mL) RSD (%)a Bias (%)b
Plasma
5   5.0 ± 0.6 12.0 0.0 5   5.8 ± 0.6 10.3 16.0
10   10.0 ± 0.2 2.0 0.0 10   10.9 ± 0.8 7.3 9.0
20   20.6 ± 0.2 1.0 3.0 20   21.2 ± 1.5 7.1 6.0
50   49.9 ± 1.3 2.6 −0.2 50   48.8 ± 0.0 0.0 −2.4
100 100.1 ± 0.7 0.7 0.1 100   97.9 ± 0.4 0.4 −2.1
200 199.8 ± 1.8 0.9 −0.1 200 196.7 ± 3.3 1.7 −1.7
500 500.7 ± 2.5 0.5 0.1 500 498.1 ± 5.1 1.0 −0.4
Liver
5   5.2 ± 0.7 13.5 4.0 5   5.4 ± 0.1 1.9 8.0
10   10.2 ± 1.0 9.8 2.0 10   9.0 ± 0.8 8.9 −10.0
20   20.2 ± 1.0 5.0 1.0 20   20.8 ± 1.7 8.2 4.0
50   50.5 ± 0.4 0.8 1.0 50   48.0 ± 2.9 1.9 −4.0
100   99.9 ± 1.5 1.5 −0.1 100 101.1 ± 1.4 1.4 1.1
200 198.4 ± 2.2 1.1 −0.8 200 201.7 ± 2.7 1.3 0.8
500 500.6 ± 0.9 0.2 0.1 500 499.8 ± 0.6 0.1 0.0
Spleen
5   5.8 ± 0.2 3.4 16.0 5   4.8 ± 0.6 12.5 −4.0
10   9.9 ± 0.6 6.1 −1.0 10   10.0 ± 0.5 5.0 0.0
20   19.3 ± 1.5 7.8 −3.5 20   19.1 ± 0.5 2.6 −4.5
50   50.7 ± 3.3 6.5 1.4 50   50.2 ± 1.0 2.0 0.4
100 101.4 ± 3.0 3.0 1.4 100 101.7 ± 6.9 6.8 1.7
200 197.3 ± 5.3 2.7 −1.3 200 199.4 ± 7.3 3.7 −0.3
500 501.1 ± 3.1 0.6 0.2 500 500.2 ± 3.4 0.7 0.0
Notes: Data are expressed as mean ± standard deviation (n = 3). aRSD (%) = [standard deviation/Cobs] × 100; bbias (%) = [(Cobs − Cnom)/Cnom] × 100.
Abbreviation: RSD, relative standard deviation.
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blood pharmacokinetic parameters of vinorelbine, which was 
  evidenced by the similar vinorelbine concentration-time profiles 
between the  111In-VNB-liposome group and   VNB-liposome 
group. From the result of vinorelbine   concentration as a function 
of radioactivity profiles (Figure 4), the linear regression between 
radioactivity and vinorelbine concentration in rats adminis-
tered with  111In-VNB-liposome was y = 725.98 × −688.13, 
where r = 0.97, showing that the radioactivity and vinorelbine 
concentration was in good correlation.
Discussion
The characteristics of the  111In-VNB-liposome including 
pharmacokinetics, biodistribution, histology, and molecular 
imaging, have been reported.21–25 In addition to these pharma-
cological studies, 111In-VNB-liposomal combination therapy 
can provide better tumor-targeting therapeutic efficacy in C26 
colorectal carcinoma-bearing mouse models.21,22,24 In this 
Table 2 Matrix effect and recovery for the determination of 
vinorelbine
Concentration (ng/mL) Matrix effect (%) Recovery (%)
Plasma
5   99.3 ± 13.7   95.3 ± 19.5
50 102.1 ± 7.2 103.9 ± 6.8
500   82.0 ± 4.6   90.9 ± 6.4
Average   94.4 ± 10.9   96.7 ± 6.6
Liver
5 102.0 ± 2.2   85.4 ± 8.2
50   95.4 ± 3.4   84.3 ± 2.4
500   88.0 ± 2.6   79.2 ± 3.2
Average   95.2 ± 7.0   82.9 ± 3.3
Spleen
5   93.0 ± 5.3   69.0 ± 2.6
50   97.2 ± 2.8   72.4 ± 2.0
500   94.5 ± 4.4   80.0 ± 3.7
Average   94.9 ± 2.1   73.8 ± 5.6
Notes: Data are expressed as mean ± standard deviation (n = 3). Set 1 = neat 
sample (vinorelbine prepared in normal saline); set 2 = postextraction fortification; 
set 3 = pre-extraction fortification; matrix effect (%) = (mean area of set 2/mean 
area of set 1) × 100; Recovery (%) = (mean area of set 3/mean area of set 2) × 100.
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Figure  2  Vinorelbine  concentration-time  curve  and  radioactivity-time  curve  in 
plasma. ♦ Vinorelbine concentration of the VNB-liposome (vinorelbine 0.3 mg/kg) 
intravenous administration group, ■ vinorelbine concentration of 111In-VNB-liposome 
(vinorelbine 0.3 mg/kg, Indium-111 2.22 MBq/rat) intravenous administration group, 
and ▲ radioactivity of of  111In-VNB-liposome (vinorelbine 0.3 mg/kg, Indium-111 
2.22 MBq/rat) intravenous administration group.
Note: Data are expressed as the mean ± standard error of the mean (n = 5 for 
each group).
Abbreviation: VNB, vinorelbine.
Table  3  Pharmacokinetic  parameters  of  vinorelbine  in 
plasma of rats administered with VNB-liposome (0.3 mg/kg 
VNB)  and  111In-VNB-liposome  (0.3  mg/kg  vinorelbine,  2.22   
MBq/rat)
VNB-liposome 111In-VNB-liposome
Blood
t1/2 (hours) 4.8 ± 1.2 3.3 ± 1.3
C0 (µg/mL) 6.27 ± 2.68 7.15 ± 1.60
AUC0–24 h (h * µg/mL) 65.5 ± 26.6 44.5 ± 31.0
Liver
Cmax (µg/g) 0.35 0.19
AUC0–24 h (h * µg/g) 5.26 3.54
Spleen
Cmax (µg/g) 2.47 2.86
AUC0–24 h (h * µg/g) 47.0 57.5
Notes: Data are expressed as the mean ± standard deviation. Pharmacokinetic 
parameters: t1/2, half life; C0, extrapolated blood concentration at time 0; AUC0–24 h, 
area under concentration–time curve; Cmax, maximum drug concentration. Blood 
sample: n = 5; liver and spleen: n = 3 for each sampling time (1, 4, and 24 hours). Mean 
concentrations at 1, 4, and 24 hours constructed the time-concentration profile of 
liver and spleen to obtain Cmax and AUC0–24 h.
Abbreviation: VNB, vinorelbine.
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Figure  3  VNB  concentration-time  curve  and  radioactivity-time  curve  in  liver  and 
spleen. ♦ Vinorelbine concentration of liver in the group of VNB-liposome (vinorelbine 
0.3 mg/kg) intravenous administration; ◊ Vinorelbine concentration of spleen in the group 
of  VNB-liposome  (vinorelbine  0.3  mg/kg)  intravenous  administration;  ■  vinorelbine 
concentration of liver in the group of 111In-VNB-liposome (vinorelbine 0.3 mg/kg, 2.22 
MBq/rat) intravenous administration; □ vinorelbine concentration of spleen in the group 
of 111In-VNB-liposome (vinorelbine 0.3 mg/kg, 2.22 MBq/rat) intravenous administration; 
● radioactivity of liver in the group of 111In-VNB-liposome (vinorelbine 0.3 mg/kg, 2.22 
MBq/rat) intravenous administration; ○ radioactivity of spleen in the group of 111In-VNB-
liposome (vinorelbine 0.3 mg/kg, 2.22 MBq/rat) intravenous administration.
Note: Data are expressed as mean ± standard error of the mean (n = 3 for each 
time point per group).
Abbreviation: VNB, vinorelbine.
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study, we have further shown a correlation between radio-
activity and chemotherapeutics of the 111In-VNB-liposome 
in the pharmacokinetics and biodistribution in the rat. The 
improved kinetic properties of vinorelbine attributable to the 
liposomal carrier were evidenced by an extended circulation 
time in rat blood and increased accumulation in the reticuloen-
dothelial system (ie, liver and spleen). The concentration of 
vinorelbine rapidly decreased from approximately 7.5 µg/mL 
to 0.2 µg/mL within 4 hours of intravenous administration of 
vinorelbine 20 mg/kg in mice.31 Different formulations, such 
as phosphatidylserine liposome and lipid microspheres, have 
been designed to improve the pharmacokinetics of vinorel-
bine and overcome the problem of its rapid elimination from 
the circulation.32 Our liposomal vinorelbine formulation 
had improved in vivo pharmacokinetic properties, achiev-
ing the highest concentration at 24 hours (204 ± 64 ng/mL) 
with approximately one thirtieth of the dose administered 
(0.3 mg/kg, Figure 2).
Liposomal drug delivery systems have been studied 
extensively as a method to increase the therapeutic index 
of chemotherapy.33,34 Our previous work has demonstrated 
that liposomal doxorubicin has a better ability to penetrate 
the blood-brain barrier.29 Nanoliposomes, which are double-
membrane lipid vesicles with a particle size from 10 nm to 
100 nm, are important carriers capable of packaging drugs 
in various drug delivery applications via the enhanced 
permeability and retention effect at leaky tumor sites. The 
reticuloendothelial system is the main turnover organ for 
liposomal drug delivery.35,36 Several investigations have 
indicated high uptake of liposome drug delivery systems in 
reticuloendothelial organs such as the liver and spleen.24,37 
Our previous study has demonstrated that reticuloendothelial 
system-rich organs, ie, the liver and spleen, are the major 
sites of uptake of liposomal vinorelbine, which is evidenced 
by calculating the accumulation of radioactivity.24 In this 
work, the average concentrations of vinorelbine in blood, 
liver, and spleen were 204 ± 64 ng/mL, 126 ± 26 ng/g, and 
1499 ± 345 ng/g, respectively, at 24 hours after administra-
tion of liposomal vinorelbine 0.3 mg/kg (Figure 3). The 
concentration of vinorelbine in the spleen was 7.3-fold higher 
than the concentration in blood.
A significant positive correlation between doxorubicin 
concentration (ng/mg) and 99mTc radiotracer (%ID/g) in tumor 
tissue has been reported previously.38 The combined thera-
peutic efficacy of the 111In-VNB-liposome has been evalu-
ated in colorectal carcinoma-bearing mice.22,23 Indium-111 
is a radionuclide commonly used for scintigraphic imaging 
(t1/2 2.81 days, 172 and 247 keV photon emission), emitting 
14.7 Auger electrons (mean energy 0.46 keV) on average 
per decay, and may also be suitable for radiotherapy.39 Our 
current study found a good pharmacokinetic correlation 
between radioactivity and vinorelbine concentration in rats 
administered the 111In-VNB-liposome. A significant positive 
correlation (r = 0.97) between vinorelbine concentration 
(ng/mL) and the Indium-111 radiotracer (%ID/g) in plasma 
was observed (Figure 4). Our work demonstrates that the 
biodistribution of radiolabeled tracer correlates well with 
chemotherapeutic vinorelbine, which can be used to estimate 
the distribution profile of vinorelbine in a liposomal formu-
lation (111In-VNB-liposome) and for drug uptake in vivo. 
However, characterization of the vinorelbine versus tracer 
uptake relationship still needs further validation.
In conclusion, this investigation identified a valid and 
reliable liquid chromatography tandem mass spectrometry 
method to determine the concentration of vinorelbine in rat 
plasma, liver, and spleen after administration of the VNB-
liposome and 111In-VNB-liposome in rats. We found that the 
nanoliposomal formulation improved the kinetic properties 
of vinorelbine and prolonged the circulation time in rat 
blood. Vinorelbine in an Indium-111-encapsulated lipo-
some exhibits a correlated concentration/radioactivity-time 
profile, providing evidence that the strategy of combinatorial 
chemoradiotherapy is practical in vivo.
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